$32.84
0.26% today
Nasdaq, Feb 28, 05:18 pm CET
ISIN
US4131971040
Symbol
HRMY

Harmony Biosciences Holdings Stock price

$32.75
-5.50 14.38% 1M
-2.87 8.06% 6M
-1.66 4.82% YTD
-0.73 2.18% 1Y
-7.21 18.04% 3Y
-4.26 11.51% 5Y
-4.26 11.51% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.72 2.15%
ISIN
US4131971040
Symbol
HRMY
Sector
Industry

Key metrics

Market capitalization $1.88b
Enterprise Value $1.64b
P/E (TTM) P/E ratio 13.05
EV/FCF (TTM) EV/FCF 7.52
EV/Sales (TTM) EV/Sales 2.30
P/S ratio (TTM) P/S ratio 2.63
P/B ratio (TTM) P/B ratio 2.84
Revenue growth (TTM) Revenue growth 22.80%
Revenue (TTM) Revenue $714.73m
EBIT (operating result TTM) EBIT $190.83m
Free Cash Flow (TTM) Free Cash Flow $218.67m
Cash position $467.19m
EPS (TTM) EPS $2.51
P/E forward 10.99
P/S forward 2.23
EV/Sales forward 1.95
Short interest 29.14%
Show more

Is Harmony Biosciences Holdings a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Harmony Biosciences Holdings Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Harmony Biosciences Holdings forecast:

8x Buy
89%
1x Sell
11%

Analyst Opinions

9 Analysts have issued a Harmony Biosciences Holdings forecast:

Buy
89%
Sell
11%

Financial data from Harmony Biosciences Holdings

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
715 715
23% 23%
100%
- Direct Costs 181 181
25% 25%
25%
534 534
22% 22%
75%
- Selling and Administrative Expenses 173 173
20% 20%
24%
- Research and Development Expense 146 146
92% 92%
20%
215 215
1% 1%
30%
- Depreciation and Amortization 24 24
1% 1%
3%
EBIT (Operating Income) EBIT 191 191
1% 1%
27%
Net Profit 145 145
13% 13%
20%

In millions USD.

Don't miss a Thing! We will send you all news about Harmony Biosciences Holdings directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Harmony Biosciences Holdings Stock News

Neutral
Business Wire
3 days ago
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced a record $201.3 million in net product revenues for the fourth quarter 2024, and full year 2024 net revenues of $714.7 million, ending the year with $576 million in cash, cash equivalents and investments on the balance sheet. The company has guided 2025 WAKIX® net revenues to $820 - $860 mi...
Neutral
Business Wire
9 days ago
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for pitolisant for the treatment of excessive daytime sleepiness (EDS) in adult patients with idiopathic hypersomnia (IH). Harmony's 2025 net revenue guidance of $820-$860 million remains unchan...
Neutral
Business Wire
10 days ago
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on February 25, 2025, at 8:30 a.m. ET to discuss the results. To participate in the call, ple...
More Harmony Biosciences Holdings News

Company Profile

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. Its product WAKIX is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded on July 25, 2017 and is headquartered in Plymouth Meeting, PA.

Head office United States
CEO Jeffrey Dayno
Employees 268
Founded 2017
Website www.harmonybiosciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today